Clinical

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Articles

“The 2-year results are very impressive and underline what SNM can offer to patients with UUI," said Andrea M. Pezzella, MD.

 Efficacy, safety of rechargeable SNM device for OAB sustained at 2 years

The rechargeable implantable neurostimulator is approved for the treatment of patients with urinary and bladder dysfunction.

FDA approves updated version of SNM device for OAB

The updated label expands the range of MRI scan parameters and allows a briefer waiting period between MRI scans.

FDA expands MRI labeling for InterStim SNM bladder and bowel control devices

Karen Nash is a medical reporter and media consultant based in Monroeville, PA.

"We typically do urodynamics when something’s unclear and confusing. I don’t always do urodynamics before doing a sling," says 1 urologist.

Do you use urodynamics when determining when to insert a sling following a prostatectomy?

Videos

Chris Du, MD, discusses findings from a study published in Neurourology and Urodynamics.

Clinical care pathway demonstrates efficacy for patients with overactive bladder

Acute urinary retention is not uncommon among men who undergo placement of a proprietary transobturator sling (AdVance) for management of postprostatectomy SUI. Still, it is rarely persistent, according to a recent study.

Study evaluates acute urinary retention after sling surgery for management of post-RP SUI

Lisette Hilton is president of Words Come Alive, based in Boca Raton, Florida.

Investigators conducted a systematic literature review and meta-analysis assessing the impact of 3 months or longer anticholinergic use on the risk of multiple subtypes of incident dementia

Anticholinergic use for 3 months or longer increases dementia risk by about 46%

“Listen. Be emphatic. Be transparent,” Pansy Uberoi, MD, MPH, advises in this interview.

Patient counseling for mesh mid-urethral sling surgery: Provide options, set expectations

The approval was based on the phase 3 EMPOWUR trial.

FDA approves vibegron for overactive bladder

Experts in prostate cancer, bladder cancer, kidney stones, OAB/incontinence, BPH, and sexual dysfunction recap all the key advances from 2020.

OAB and Incontinence